Eva Blondeaux
Overview
Explore the profile of Eva Blondeaux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Blondeaux E, Xie W, Carmisciano L, Mura S, Sanna V, De Laurentiis M, et al.
EClinicalMedicine
. 2024 Apr;
70:102501.
PMID: 38685923
Background: Intermediate clinical endpoints (ICEs) are frequently used as primary endpoint in randomised trials (RCTs). We aim to assess whether changes in different ICEs can be used to predict changes...
12.
Blondeaux E, Partridge A, Lambertini M
JAMA
. 2024 Apr;
331(14):1234.
PMID: 38592390
No abstract available.
13.
Lambertini M, Blondeaux E, Agostinetto E, Hamy A, Kim H, Di Meglio A, et al.
JAMA
. 2023 Dec;
331(1):49-59.
PMID: 38059899
Importance: Young women with breast cancer who have germline pathogenic variants in BRCA1 or BRCA2 face unique challenges regarding fertility. Previous studies demonstrating the feasibility and safety of pregnancy in...
14.
Trevisan L, Godino L, Battistuzzi L, Innella G, Luppi E, Buzzatti G, et al.
Fam Cancer
. 2023 Nov;
23(2):197-207.
PMID: 37968543
Healthy carriers of BRCA1/2 pathogenic variants (PVs) may benefit from risk-reducing measures of proven efficacy. The main approach to identify these individuals is cascade testing, and strategies to support this...
15.
Scavone G, Ottonello S, Blondeaux E, Arecco L, Scaruffi P, Stigliani S, et al.
Cancers (Basel)
. 2023 Oct;
15(20).
PMID: 37894292
The combination of cyclin-dependent kinase (CDK) 4/6 inhibitors with endocrine therapy is the standard treatment for patients with HR+/HER2- advanced breast cancer. Recently, this combination has also entered the early...
16.
Lambertini M, Blondeaux E, Bisagni G, Mura S, De Placido S, De Laurentiis M, et al.
EClinicalMedicine
. 2023 May;
59:101931.
PMID: 37256095
Background: Prior exposure to adjuvant endocrine therapy (ET) and timing to recurrence are crucial factors for first-line treatment choices in patients with hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC) and in...
17.
Blondeaux E, Arecco L, Punie K, Graffeo R, Toss A, De Angelis C, et al.
Cancer Treat Rev
. 2023 Feb;
114:102522.
PMID: 36739824
Approximately 10% of breast cancers are associated with the inheritance of a pathogenic variant (PV) in one of the breast cancer susceptibility genes. Multiple breast cancer predisposing genes, including TP53,...
18.
Del Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, et al.
Lancet Oncol
. 2022 Nov;
23(12):1571-1582.
PMID: 36370716
Background: Previous analyses of the GIM (Gruppo Italiano Mammella) 2 study showed that addition of fluorouracil to epirubicin, cyclophosphamide, and paclitaxel in patients with node-positive early breast cancer does not...
19.
Blondeaux E, Lambertini M, Buzzatti G, Bruzzone C, Baraga M, Pisani R, et al.
J Genet Couns
. 2022 Aug;
32(1):140-152.
PMID: 36036895
Several models of genetic counseling have been proposed to tackle the increasing volume of individuals requiring access to BRCA testing. Few data are available on patient experience and retention of...
20.
Perachino M, Poggio F, Arecco L, Blondeaux E, Spinaci S, Marrocco C, et al.
Cancer J
. 2022 May;
28(3):176-182.
PMID: 35594464
Survivorship has become a crucial component in breast cancer care. For women who have not completed their family planning, conceiving at the end of anticancer treatments should not be discouraged...